Regeneron Pharma (REGN) Tops Q2 EPS by 17c; EYLEA Sales Rose 26%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Nasdaq, S&P tumble as Netflix, chip stocks drag; AmEx boosts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Nasdaq tumbles, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Jabil falls after placing CEO on paid leave amid internal investigation
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Regeneron Pharma (REGN) Price Target Raised to $425 at Deutsche Bank
August 5, 2014 12:54 PM EDTDeutsche Bank reiterated a Buy rating on Regeneron Pharma (NASDAQ: REGN) and raised its price target to $425.00 (from $410.00).
Analyst Robyn Karnauskas said, "Eylea 2Q sales in the US were $415M vs. $410M consensus. In 1Q14 the... More
Roth Capital Comments on Regeneron (REGN) Following Q2 Results; Affirms 'Buy' Rating
August 5, 2014 12:29 PM EDTRoth Capital affirms Regeneron Pharmaceuticals (Nasdaq: REGN) at Buy with a target price of $399 following Q2 results.
Analyst Joseph Pantginis commented, REGN 2Q14 results show a 45% year-to-year growth in revenue as well as a 26% Eylea net sales growth, demonstrating the effective market penetration of the product. Recall that Eylea is already approved in the U.S. and E.U. for wet AMD and macular edema... More
